The administration of ephedrine and caffeine (E+C) has been proposed to promote weight loss by increasing energy expenditure and decreasing food intake. We tested this hypothesis in six lean (4-9% body fat) and six mildly to moderately obese (13-44% body fat) monkeys studied during a 7-wk control period, an 8-wk drug treatment period, and a 7-wk placebo period. During the drug treatment period, the monkeys were given ephedrine (6 mg) and caffeine (50 mg) orally three times per day. At the end of each period, a glucose tolerance test was performed, energy expenditure was measured, and body composition was determined. Treatment with E+C resulted in a decrease in body weight in the obese animals (P = 0.06). This loss in weight was primarily the result of a 19% reduction in body fat. Drug treatment also resulted in a decrease in body fat in the lean group (P = 0.05). Food intake was reduced by E+C only in the obese group (P < 0.05). Nighttime energy expenditure was increased by 21% (P < 0.03) in the obese group and 24% (P < 0.01) in the lean group with E+C treatment. Twentyfour-hour energy expenditure was higher in both groups during drug treatment. E+C did not produce systematic changes in glucoregulatory variables, whereas plasma leptin concentrations decreased in both groups with drug treatment. Overall, these results show that E+C treatment can promote weight loss through an increase in energy expenditure, or in some individuals, a combination of an increase in energy expenditure and a decrease in food intake.
INTRODUCTION
Obesity is characterized by an imbalance between energy intake and expenditure, resulting in a net increase in the storage of body energy primarily as fat. This imbalance is the result of either a high energy intake, low energy expenditure, or a mixture of the two conditions. A reduced rate of energy expenditure has been shown to contribute to the development of obesity in humans (1) and genetically obese strains of rodents (2) . The mechanism for this decreased energy expenditure has not been fully established, but one contributing factor may be low sympathetic nervous system (SNS) activity. Studies with rodents (3) and human subjects (4) have shown that low SNS activity can contribute to the development of obesity. These observations suggest that obesity may be treated effectively by increasing energy expenditure with the use of sympathomimetic agonists. The use of an ephedrine and caffeine mixture (E+C) is one treatment that has shown promise as an antiobesity agent, presumably acting at least in part by SNS-mediated stimulation of energy expenditure (5, 6) .
Ephedrine has been shown to increase energy expenditure in humans (7) . The mechanism for this effect appears to be related to stimulation of release of norepinephrine (8) and direct agonistic stimulation of adrenoreceptors (9) . Both of these actions may stimulate energy expenditure through increases in intracellular concentrations of cyclic AMP. The ephedrine-induced stimulation of energy expenditure is further enhanced when ephedrine is administered in combination with methylxanthines such as caffeine (10) . The mechanism for methylxanthine enhancement of ephedrine is likely the result of inhibition of phosphodiesterase enzyme activity and antagonism of the inhibitory effect of adenosine on norepinephrine release (11) . The presence of plausible modes of action for ephedrine-and caffeine-induced increases in energy expenditure suggest that continued administration of a combination of the 2 drugs may have potent antiobesity actions.
A study in postobese and lean volunteers first showed in humans that E+C was more effective than ephedrine alone at raising energy expenditure and E+C could effectively raise energy expenditure in individuals predisposed to obesity (12) . Several studies have shown that E+C can effectively cause weight loss in humans (13) (14) (15) . The contribution of increased energy expenditure or decreased food intake to weight loss with E+C treatment is still not firmly established, with studies reportEnergy expenditure, body composition, and glucose metabolism in lean and obese rhesus monkeys treated with ephedrine and caffeine ing either food intake (10) or energy expenditure (16) changes as the major contributors to weight loss. Additional research has also been needed to determine the role these drugs may play in altering glucose metabolism. The purpose of the present study was to determine the effect of administration of E+C on food intake and energy expenditure in lean or mildly to moderately obese rhesus monkeys under carefully controlled conditions. Additionally, frequently sampled glucose tolerance tests were performed to determine the effect of E+C on glucose metabolism, and dual-energy X-ray absorptiometry (DXA) measurements were used to assess body composition.
MATERIALS AND METHODS

Experimental design
Twelve adult male rhesus monkeys (Macaca mulatta) ranging in age from 8 to 20 y were selected for this experiment. The monkeys were then assigned to 1 of 2 groups based on percentage body fat: lean (4-9% body fat) or obese (13-44% body fat).
All monkeys were individually housed in stainless steel cages with inside dimensions of 89 cm wide ϫ 86 cm deep ϫ 86 cm high. The cages contained food hoppers and spigots to allow the animals continuous access to water. The rooms were maintained at Ϸ21 ЊC and lighted from 0600 to 1800. The animals were allowed to eat commercial, nonpurified biscuits (#5037; Ralston Purina Co, St Louis: 15% of energy as protein and 12% as fat, with beef tallow as the primary fat source) ad libitum between 0800 and 1500. Intake, accounting for spillage, was measured daily.
The monkeys were tested in a 7-wk control period followed by an 8-wk drug treatment phase, and, finally, a 7-wk placebo period. During the drug treatment phase, the animals were given ephedrine hydrochloride (6 mg, Efedrin; Hammer Corp, Atlanta) and caffeine (50 mg, Jet-Alert; Wendt Laboratories, Belle Plaine, MN) orally 3 times/d. The ephedrine and caffeine capsules were hidden in a small piece of fruit for administration to the monkeys. The E+C dose used in this experiment was 18 mg ephedrine and 150 mg caffeine/d. This dose was similar to the dose used in many human studies when normalized by using weight 3/4 or weight 2/3 to adjust for interspecies differences in body weight (17, 18) . Previous tests of the dose in the monkeys had shown no evidence of unusual behavior or harmful side effects. Placebo was given 3 times per day during the final phase of the experiment. During all of the phases, food intake was measured daily and blood samples and body weights were taken weekly. Additionally, oxygen consumption was measured in the fourth and fifth weeks of all phases, and frequently sampled glucose tolerance tests and body-composition measurements were completed in the sixth and seventh weeks of all phases. This protocol was approved by the Institutional Animal Care and Use Committee at the University of Wisconsin-Madison.
Oxygen consumption
The monkeys were placed individually inside a transparent metabolic chamber with inside dimensions of Ϸ75 cm wide ϫ 75 cm deep ϫ 80 cm high. The duration of the calorimetry measurements was Ϸ30 h. The animals had visual and auditory contact with other animals the entire time they were in the chamber.
The flow rate of filtered, compressed air entering the chamber was regulated. Exhaust air was dried and continuously sampled at a rate of 100 mL/min for analysis of oxygen content (R-1 Flow Control Unit, S-3A Oxygen Readout/Control Unit; Applied Electrochemistry, Inc, Sunnyvale, CA; now AMETEK, Pittsburgh). Outputs from the flow meter and oxygen analyzer were recorded every 10 min by using an IDAC 1000 interface (IDAC, Amherst, NH) and Apple Macintosh SE/30 computer (Apple Computer, Inc, Cupertino, CA). The chamber was calibrated by burning ethanol and measuring oxygen consumption. Accuracy of the calorimetry system was 96%. Energy expenditure was calculated from oxygen consumption by using the term 20.7 kJ/L oxygen. This value was calculated from the food quotient of the diet (the predicted respiratory quotient, assuming nutrient oxidation matches diet composition). For analysis, energy expenditure was divided into morning (0600-1200), afternoon (1200-1800), overnight (1800-0600), and 24-h measurements.
Behavioral observations
Thirty-minute behavioral observations were performed twice during the control and placebo phases and 3 times during the drug treatment period. The observations were made at 1200, immediately after the second drug or placebo administration of the day. The behavior of the animals was scored according to the amount of time spent lying down, sitting, standing, moving horizontally, or moving vertically. Notes were also made regarding any unusual behaviors.
Body composition
Fat mass, lean mass, and percentage body fat were determined by DXA (model DPX-L; Lunar Corp, Madison, WI) (19, 20) . Animals were sedated with ketamine hydrochloride (15 mg/kg, intramuscularly) plus acepromazine (2 mg intravenously) for additional muscle relaxation and scanned in the supine position.
Frequently sampled glucose tolerance test
Frequently sampled glucose tolerance tests were conducted according to the Modified Minimal Model protocol (21, 22) . The animals were food deprived overnight and then anethestized with ketamine (15 mg/kg intramuscularly) and diazapam (1 mg/kg intramuscularly), with supplemental ketamine as needed. A venous catheter was placed for sample collection and administration of glucose and tolbutamide. Four baseline blood samples were taken, followed by administration of a 300-mg/kg glucose bolus over 1 min. Blood samples were then drawn at 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 19, 22, 23, 24, 25, 27, 30, 40, 50, 60 , 70, 80, 90, 100, 120, 140, 160, and 180 min after glucose administration. Tolbutamide (5 mg/kg) was infused 20 min after glucose administration. Data were analyzed by the Minimal Model Method (23) .
Plasma glucose was measured by the glucose oxidase method (model 23A; Yellow Springs Instruments, Yellow Springs, OH). Insulin was measured by double-antibody radioimmunoassay (Binax, South Portland, ME). Leptin was also measured by radioimmunoassay of baseline blood samples (LINCO Research, Inc, St Louis).
Blood samples
Weekly blood samples were taken after an overnight fast in all of the animals. Radioimmunoassay analyses of triiodothyronine (Diagnostic Products Corporation, Los Angeles) and cortisol (INCSTAR, Stillwater, MN) were completed on all samples.
Statistical analysis
All results are presented as means ± SDs. Comparisons between the lean and obese groupings of animals at the start of the control period were completed by using one-way analysis of variance (ANOVA). Comparisons between treatment phases were made by using repeated-measures ANOVA in which the factors were individual animal, treatment (control, drug, and placebo), group (obese or lean), and time. Significant (P < 0.05) treatment-by-group interactions were present for basal glucose, food intake, weight, fat mass, afternoon energy expenditure, leptin, and triiodothyronine. Treatment comparisons of these variables were analyzed within groups by paired t test. Both groups were matched for age before the start of the experiment and no consistent age-related effects were noticed for any of the variables at any of the assessment periods. All analyses were completed by using the JMP statistical program (SAS Institute, Cary, NC).
RESULTS
Characteristics of the obese and lean groups of monkeys are summarized in Table 1 . As expected, body weight (P < 0.01), lean tissue mass (P = 0.05), and fat mass (P < 0.01) were higher in the obese group than in the lean animals. This increased body size was not associated with hyperphagia because food intake was actually higher in the lean than in the obese group. Total energy expenditure (kJ/min) was not different between groups during any period of the day (P > 0.10); however, 24-h energy expenditure expressed as a function of lean body mass was lower in the obese animals ( Figure 1 ). Leptin (P < 0.01), basal insulin (P = 0.03), and glucose (P = 0.02) were all higher in the obese than in the lean animals. Insulin sensitivity and disposition index were lower (P < 0.10) in the obese than the lean group, whereas other test variables did not differ significantly between the groups.
The effect of E+C treatment on food intake is illustrated in Figure 2 . Food intake, through 8 wk of drug treatment, decreased by 24% (P = 0.01) in the obese animals, whereas E+C treatment did not alter food intake in the lean group. Food intake increased in both the obese (P = 0.02) and lean (P = 0.01) groups during the placebo phase when compared with the drug treatment phase. Food intake also tended to be higher in the placebo phase than in the control period, although these differences were not significant.
The effect of E+C treatment on body weight and composition is summarized in Table 2 . Eight weeks of drug treatment resulted in a 7.5% decrease in body weight in the obese group (P = 0.057) whereas no significant changes were noticed in the lean animals. Weight loss began the first week of drug treatment in the obese animals and continued throughout the drug treatment phase. This change in body weight was primarily the result of a 19% decrease in body fat in the obese animals (P = 0.075). Similarly, E+C treatment resulted in a decrease in body fat in the lean animals but this was countered by a slight increase in lean body mass and resulted in no net change in total body mass. After E+C treatment, the obese and lean animals gained weight; this weight gain plateaued in the fifth week of the placebo phase. Both groups of animals tended to increase in body weight after cessation of the E+C treatment, which was attributable to slight increases in both lean tissue mass and fat mass in the lean group and increases primarily in lean mass in the obese animals. Final 1 P values for one-way ANOVA between the obese and lean groups.
FIGURE 1.
Twenty-four-hour energy expenditure plotted against lean body mass for both the lean (n = 6) and obese (n = 6) groups of monkeys during the control phase of the experiment. body weights in the placebo and control periods were not significantly different in the obese group, whereas body weight was greater in the placebo than in the control period in the lean monkeys (P = 0.001).
E+C treatment resulted in increased energy expenditure in both the obese and lean animals ( Table 3) . Drug treatment increased overnight energy expenditure by ≥ 20% in both groups. Morning and 24-h energy expenditure were also significantly increased by E+C treatment (P < 0.001). Afternoon energy expenditure, however, increased only in the lean group (P < 0.05). Energy expenditure was significantly lower during the placebo period than the drug treatment period in both groups and at all time periods. Placebo and control 24-h energy expenditures were not significantly different (P > 0.10). No systematic changes in behavior or activity were observed between treatment phases in either the obese or lean group of monkeys.
Frequently sampled glucose tolerance tests were performed on each of the animals in all phases of the experiment ( Table 4) . No treatment effects (P > 0.10) were detected for basal insulin, insulin sensitivity, glucose effectiveness, acute insulin response to glucose, second-phase insulin response to glucose, insulin response to tolbutamide, and disposition index when comparing the control, drug, and placebo phases. Basal insulin did show a trend toward a decrease during the drug treatment phase when compared with the control (P = 0.072) and placebo (P = 0.093) phases. Glucose disappearance rate tended to increase between the drug and placebo phases of the experiment (P = 0.075). Treatment response was similar between the obese and lean animals for all of the glucose-tolerance-test variables except basal glucose. The lean group of animals showed a significant increase in basal glucose during the placebo period when compared with the control and drug phases (P < 0.05), whereas no significant differences were observed between treatment phases in the obese group (P > 0.10).
Cortisol concentrations (Figure 3) showed no significant differences between the control and drug treatment phases in either the lean or obese groups (P > 0.10). Triiodothyronine concentrations were increased by 10% with E+C treatment in the obese EPHEDRINE PLUS CAFFEINE TREATMENT AND ENERGETICS 45 monkeys (P = 0.02), whereas concentrations of this hormone were not altered with drug treatment in the lean animals ( Figure  4) . Triiodothyonine concentrations also decreased (P < 0.05) after cessation of drug treatment in the obese and lean groups. Triiodothyronine concentrations during the last 5 wk of the placebo period were not different from values measured during the control period in both the lean and obese monkeys (P > 0.10). Plasma leptin concentrations were lower in the drug treatment phase in both the lean (P = 0.10) and obese (P < 0.09) groups of animals ( Figure 5 ). Plasma leptin concentrations also tended to increase after cessation of E+C treatment in both groups of animals.
DISCUSSION
This study showed that E+C given for 8 wk induced weight loss in obese rhesus monkeys, whereas body weight was not significantly altered in lean monkeys. Several studies with human volunteers (13, 15, 24) have shown that administration of E+C along with a 5-MJ/d diet causes a significant decrease in body weight in obese individuals. Similarly, studies in obese mice (16) and rats (25) have shown that E+C induces a significant decrease in body weight without concurrent food restriction. These results agree with the present finding that E+C decreased body weight in obese monkeys allowed free consumption of food. Changes in body weight during treatment with these drugs, however, appeared to be dependent on the initial body composition of the animals. In the present study, body weight was not significantly changed in the lean group. This probably reflects the fact that the lean group had a very low body fat content and despite a significant decrease in body fat, changes in total body weight were not large enough for significant differences to be detected. The observation of increases in body weight in both the lean and obese groups of animals after the 46 RAMSEY ET AL drug treatment phase also supports the idea that E+C reduces body weight.
Changes in body weight during E+C treatment were primarily the result of decreases in fat mass. Fat mass decreased in both lean and obese groups of monkeys whereas lean tissue mass was not changed significantly with drug treatment. This observation agrees with previous animal studies that show E+C treatment induces a dramatic decrease in total body fat. Dulloo and Miller (26) showed that body fat was reduced 75% in obese (fa/fa) Zucker rats after E+C treatment for 15 wk. Inclusion of EPHEDRINE PLUS CAFFEINE TREATMENT AND ENERGETICS 47 FIGURE 3. Cortisol plotted against time during the 3 treatment phases. Repeated-measures ANOVA was used to test for differences in cortisol concentrations between the treatment phases. No significant differences were detected between the treatment phases (P > 0.10).
FIGURE 2.
Food intake plotted against time during the 3 treatment phases. Repeated-measures ANOVA was used to test for differences in food intake between the treatment phases. Food intake was significantly lower in the drug treatment phase than in the control and placebo phases in the obese animals (P < 0.05). In the lean animals, food intake was significantly greater during the placebo phase than during the drug treatment phase (P < 0.05). E+C in the diets of growing pigs was also shown to cause a 27% decrease in lipid accretion and to accelerate muscle protein deposition over a 6-wk period (27) . After cessation of E+C, weight gain was the result of increases in both lean and fat mass in both groups of monkeys. The mechanism for the preferential decrease in fat mass during administration of E+C remains largely unknown. However, some evidence suggests that direct stimulation of ␤-adrenergic receptors is a major contributor to this response. Ephedrine has both indirect sympathomimetic activity, by causing release of norepinephrine from sympathetic nerve terminals, and direct agonist activity on ␤-adrenergic receptors (5). ␤-Adrenergic agonists have been studied extensively and shown to decrease carcass fat content (28) . Research with ␤ 3 -agonists has also shown a decrease in carcass adipose tissue in rats after treatment with a highly selective agonist (29) . These results suggest that the decreases in body fat associated with E+C treatment may be the result of interaction between ephedrine and ␤ 3 or other ␤-receptors.
Ultimately, changes in body composition are the result of an imbalance between energy intake and energy expenditure. E+C treatment significantly changed food intake in only the obese group of monkeys, whereas energy expenditure tended to increase in both groups during drug treatment. These results show that changes in energy expenditure contributed to changes in body weight in both groups, whereas a decrease in food intake also contributed to weight loss in the obese animals.
The effect of E+C on food intake, however, is variable, with some experiments reporting a major decrease and others reporting no change in intake during drug treatment. Chronic treatment of obese human patients with E+C resulted in weight loss, which was attributed primarily to the anorectic effect of the drug mixture (6) . In another study, a decrease in food intake was estimated to account for 80% of the weight loss in human volunteers after 8 wk of E+C treatment (30) . Food intake has also been shown to decrease in obese (fa/fa) Zucker rats after administration of E+C (26) . Studies with monosodium glutamate-induced obese mice, however, have shown weight loss without a change in food intake after administration of E+C (16) . The different findings among studies may reflect the type of obesity the subjects had. The obese group of monkeys, similar to the human (6) and Zucker rat (26) studies, showed a decrease in food intake during E+C treatment whereas food intakes in the lean group remained unaltered. Curiously, the maintenance of obesity in the present study does not appear to be the result of hyperphagia because the obese group of monkeys actually had lower daily food intakes than the lean group, despite having a larger body size. Total energy expenditure was not different between the lean and obese groups, despite the fact that the obese animals had a larger total mass and lean body mass than the lean animals. When energy expenditure was expressed as a function of lean body mass ( Figure 1 ) the obese animals had a lower energy expenditure than the lean animals. This suggests that a low energy expenditure was probably a major contributor to the obesity of this group of monkeys. It is possible that the different responses in food intake noticed between studies may reflect obesity of different etiology and differences in sensitivity or activity of food intake regulatory systems.
E+C treatment resulted in a decrease in serum leptin concentrations in both the lean and obese groups of monkeys. Leptin administration to ob/ob mice (31) and diet-induced obese mice (32) has been shown to decrease food intake. Decreases in serum leptin concentrations in both groups of monkeys suggest that at least one mechanism is induced by E+C treatment that may counteract processes that would decrease food intake. The decrease in serum leptin concentrations during E+C administration may be the result of stimulation of ␤ 3 -adrenergic receptors by ephedrine because previous research showed that activation of ␤ 3 -adrenergic receptors suppresses leptin gene expression (33) . The changes in serum leptin concentrations may also simply reflect changes in body fat content during drug treatment. Experiments measuring leptin concentrations in rodents (34, 35) , humans (35, 36) , and monkeys (37) have shown that leptin has a strong positive correlation with body fat. Decreased plasma leptin concentrations in the monkeys with E+C treatment are probably related to the decreased body fat measured in these animals during drug treatment. Similarly, increases in plasma leptin concentrations in the lean animals after cessation of E+C treatment may reflect increases in body fat during this period.
In contrast with the mixed results obtained regarding food intake with E+C, this drug combination has been consistently shown to increase energy expenditure. Studies with rodents (16, 26) and short-term measurements in humans (38) showed that E+C increases total energy expenditure. Additionally, E+C was shown to increase resting metabolic rate (25) and meal-induced thermogenesis (39, 40) . These results are consistent with the present observation that E+C tended to increase energy expenditure in both the lean and obese groups of monkeys. Evening or resting energy expenditure was significantly increased in both the lean and obese animals. The thermic effect of meals was not specifically measured in this experiment, but drug-treated animals did tend to have higher oxygen consumption in the morning, when most of the food was consumed. Total or 24-h energy expenditure was also higher in E+C-treated monkeys than in controls. The fact that energy expenditure decreased in both groups at all time points after E+C was stopped also supports increased energy expenditure as a major effect of treatment with this combination of drugs. Overall, resting and 24-h energy expenditure were increased by E+C treatment.
Increases in energy expenditure during E+C treatment appear to be mediated through ephedrine-induced stimulation of ␤-adrenergic receptors. ␤ 1 -, ␤ 2 -, and ␤ 3 -adrenoceptors all may play a role in the thermogenic action of ephedrine but the ␤ 3 -adrenoceptor has been proposed to be responsible for ≥ 40% of this thermogenic response in humans (41) . Experiments using specific ␤ 3 -adrenergic agonists have shown that stimulation of this receptor results in increased thermogenesis (42, 43) primarily by increasing resting metabolic rate (29) . This is consistent with the finding that the most dramatic changes in energy expenditure in the monkeys occurred in resting energy expenditure.
The site of action for ephedrine-induced thermogenesis has not been firmly established, but one study in humans showed that Ϸ50% of the increase in oxygen consumption occurs in skeletal muscle (44) . It is probable that skeletal muscle is also a significant contributor to the increased energy expenditure observed during drug treatment in the monkeys. Adult rhesus monkeys have also been shown to have functional brown adipose tissue (45) , so it is possible that this tissue may also contribute to the increased energy expenditure with E+C treatment. Additional research will have to be performed, however, to determine the cellular mechanisms responsible for the increased energy expenditure with E+C treatment.
Blood concentrations of triiodothyronine were elevated during E+C treatment in the obese group of monkeys. Previous experiments have shown that treatment with ephedrine (46) or E+C (47) at least transiently increase the ratio of triiodothyronine to thyroxine. This information suggests that changes in thyroid hormone concentrations may partially contribute to the elevated energy expenditure rate in the obese animals during drug treatment. The lack of a significant increase in triiodothyronine concentrations with E+C treatment in the lean group, however, show that changes in this hormone are not essential for E+C-induced elevations of energy expenditure.
Frequently sampled glucose tolerance tests were performed on the monkeys to determine the role E+C may play in carbohydrate metabolism. At the start of the experiment, the obese group had higher basal insulin and basal glucose concentrations and lower insulin sensitivity than the lean group. These results agree with previous reports of hyperinsulinemia and insulin insensitivity for obese compared with lean rhesus monkeys (48, 49) and humans (50) . A trend toward a decrease in basal insulin and glucose disappearance rate were the only changes that occurred between the control and drug treatment phases. Previous experiments have shown that ephedrine acutely increases plasma glucose and insulin (6, 7) in a dose-dependent manner in humans. In the present study, it is likely that short-term changes in plasma insulin and glucose had disappeared by the time that these variables were measured. The decrease in insulin in the monkeys was probably not a direct effect of drug treatment but may have been the result of a decrease in body fat during the experiment. Similarly, slight changes in other glucose tolerance values tended to occur during periods of greatest weight change in both the lean and obese animals, and these changes were probably the result of changes in body fat mass. Additional experiments of longer duration are needed to determine whether this treatment would have been beneficial in the treatment of hyperinsulinemia in the obese group of monkeys.
Treatment with a mixture of ephedrine and caffeine effectively decreased fat mass in both lean and obese rhesus monkeys. The decrease in fat mass was primarily due to an increase in resting energy expenditure in the lean animals, whereas increased resting energy expenditure and a decrease in food intake both contributed to loss of fat mass in the obese group. Overall, E+C promoted weight loss by increasing energy expenditure in both groups, although additional research is needed to determine whether this drug mixture also has beneficial long-term antidiabetic effects.
